title: Successful treatment of macular retinoblastoma with superselective ophthalmic artery infusion of melphalan.
abstract: OBJECTIVE
  To report our experience with superselective ophthalmic artery infusion of melphalan (SOAIM) for macular retinoblastoma to obtain tumor control while preserving as much useful vision as possible.
  
  
  METHODS
  Five patients with newly diagnosed unilateral retinoblastoma involving the macula were selected within a group of patients eligible for SOAIM as the primary treatment.
  
  
  RESULTS
  The mean tumor basal dimension and thickness in this group of five patients with macular retinoblastoma were 11.6 and 12.3 mm, respectively. The stage at diagnosis ranged from II to VB (Reese-Ellsworth) or B to D (International Classification System). Tumor regression with SOAIM was achieved in all cases with regression patterns type I in four cases and III in one case.
  
  
  CONCLUSIONS
  SOAIM can be of value in the treatment of macular retinoblastoma. It may allow the salvage of the residual eyesight with a low rate of complications due to the local and systemic toxicity related to chemotherapy.
authors.forename: Theodora
authors.initials: T
authors.lastname: Hadjistilianou
authors.forename: Gianni
authors.initials: G
authors.lastname: Coriolani
authors.forename: Sandra
authors.initials: S
authors.lastname: Bracco
authors.forename: Paola
authors.initials: P
authors.lastname: Gennari
authors.forename: Mauro
authors.initials: M
authors.lastname: Caini
authors.forename: Alfonso
authors.initials: A
authors.lastname: Cerase
authors.forename: Daniela
authors.initials: D
authors.lastname: Galimberti
authors.forename: Sonia
authors.initials: S
authors.lastname: De Francesco
authors.forename: Mariacarla
authors.initials: M
authors.lastname: De Luca
authors.forename: Domenico
authors.initials: D
authors.lastname: Mastrangelo
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage* / Q000627:therapeutic use; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007261:Infusions, Intra-Arterial; D008297:Male; D008558:Melphalan / Q000008:administration & dosage* / Q000627:therapeutic use; D009367:Neoplasm Staging; D009880:Ophthalmic Artery; D019572:Retinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012175:Retinoblastoma / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D018906:Antineoplastic Agents, Alkylating; D008558:Melphalan